Skip to main content
MYGNMyriad Genetics, Inc.Sell4.0·$6.02

Myriad Genetics (MYGN) Q3 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+44.9% vs estimateEPS -$0.11 vs -$0.20 estCurrent verdict Sell 4.0/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
-$0.11
Estimate
-$0.20
Surprise
+44.9%
Score today
4.0/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q3 2026

How the report landed

Myriad Genetics (MYGN) reported a narrower loss than forecast — adjusted EPS of -$0.11 against the -$0.20 estimate (a 44.9% beat on a still-unprofitable quarter).

Around the report

Coverage in the report window

  • Myriad Genetics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance — fiscal.ai, 2026-11-04
  • Myriad Genetics Q3 2026 Earnings Call Transcript — benzinga, 2026-11-04
  • Myriad Genetics Raises FY2026 Sales Guidance from $770.000M-$790.000M to $780.000M-$790.000M vs $777.921M Est — benzinga, 2026-11-04
Current read · as of 2026-11-05

Where TrendMatrix's rating stands now

TrendMatrix currently rates MYGN Sell at 4.0/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +44.9% surprise compares with a +6.5% four-quarter average.

What argues against it

  • Target reached (-35.1% upside)
  • Quality below floor (3.6 < 4.0)
  • Momentum score 4.3/10 — below 4.5 minimum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$6.02
Stop
$5.60

Risk check: RSI 70 — a level conventionally read as overbought; gains at these levels often lean on momentum.

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare context

MYGN at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$575.8M
P/E (fwd)
-10.2
52-week range
$2.74–$8.09
Off 52-week high
25.6%
RSI (14)
70
Volume vs avg
0.68×
Score today
4.0/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › MYGN › Earnings › Q3 2026 earnings